Potential Protective Role of SGLT-2 Inhibitors for Chemotherapy-induced Cardiotoxicity

Summary

The purpose of this study is to evaluate whether dapagliflozin reduces chemotherapy-induced cardiotoxicity in participants with breast cancer treated with (neo-)adjuvant Anthracycline-based chemotherapy +/- trastuzumab. The study aims to describe the efficacy for dapagliflozin as compared to standard of care. Participants will be recruited in participating centers, where they are planning on starting (neo-) adjuvant ACT-based chemotherapy and/or trastuzumab for stage I-III breast cancer.

Eligibility

Inclusion Criteria:

* Chemotherapy-naive patients, scheduled for antracycline +/- trastuzumab treatment in the (neo-)adjuvant setting for stage I-III breast cancer.
* Adult women between 18 and 70 years of age
* eGFR\>25 ml/min/1.7 mq
* ECOG score 0-2Consent form signed. Female patients of childbearing potential (not surgically sterilized and between menarche and 1 year post menopause) must have a negative result from a serum pregnancy test performed within 7 days of randomization and on the day of first study treatment prior to the initiation of study treatment. Women of childbearing potential must agree to use highly effective contraceptive measures from the time of informed consent through 7 months after last dose of study drug. Women of childbearing potential willing to use highly effective contraceptive measures from the time of informed consent through 7 months after last dose of study drug .

Exclusion Criteria:

* Left ventricular ejection fraction (LVEF) \<53%\*
* Valvular heart disease.
* Previous malignancy requiring treatment with anthracyclines or chest radiotherapy.
* A life expectancy of ≤12 weeks.
* Currently pregnant (confirmed with positive pregnancy test performed from -7 to -1 days prior to start study drug) or unwilling to adopt highly effective contraceptive method.
* Currently breast-feeding women
* History of hypersensitivity to dapagliflozin or any of the excipients of the product.
* History of Diabetic Ketoacidosis (DKA) requiring medical intervention (e.g. emergency room visit and/or hospitalization) within 1 month prior to enrolment visit.
* Type 1 diabetes mellitus

Conditions3

Interventions1

Related trials

• Cardiotoxicity in Breast Cancer Patients — Helwan University
• Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMI — Mohammad Hussien Tantawy Soliman
• Dapagliflozin in STEMI — Ottawa Heart Institute Research Corporation
• Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity — Tanta University
• Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy — University of Edinburgh
• SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AF — Region Örebro County
• SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease — The University of Hong Kong
• SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus — Chinese University of Hong Kong

Browse More Trials